Video

Dr. Weisel on INSIGHT MM Analysis of Duration of Therapy in Myeloma

Author(s):

Katja Weisel, MD
Conference|International Myeloma Society Annual Meeting

Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.

Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.

<<< View more from the 17th International Myeloma Workshop

Related Videos
Mansi R. Shah, MD
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Related Content
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Urothelial Carcinoma | Image Credit: © Sebastian Kaulitzki- stock.adobe.com
December 19th 2024

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 16th 2024

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Breast cancer / stock.adobe.com
December 16th 2024

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer